Polycomb-mediated loss of miR-31 activates nik-dependent NF-κB pathway in adult T cell leukemia and other cancers

Cancer Cell

Volumn 21, Issue 1, 2012, Pages 121-135

  Yamagishi, Makoto ^a,b   Nakano, Kazumi ^a   Miyake, Ariko ^a   Yamochi, Tadanori ^a   Kagami, Yayoi ^a   Tsutsumi, Akihisa ^a   Matsuda, Yuka ^a   Sato Otsubo, Aiko ^c   Muto, Satsuki ^a,c   Utsunomiya, Atae ^d   Yamaguchi, Kazunari ^e   Uchimaru, Kaoru ^a   Ogawa, Seishi ^c   Watanabe, Toshiki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b The Japan Foundation   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d IMAMURA GENERAL HOSPITAL   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 31; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE LOSS; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; UPREGULATION;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 84862907856     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.12.015     Document Type: Article

References (37)

1. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
2. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
3. Bellon M., Lepelletier Y., Hermine O., Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 2009, 113:4914-4917.
4. Caretti G., Di Padova M., Micales B., Lyons G.E., Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 2004, 18:2627-2638.
5. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
6. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
7. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., Ustun C., Rao R., Fernandez P., Chen J., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
8. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
9. Hironaka N., Mochida K., Mori N., Maeda M., Yamamoto N., Yamaoka S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 2004, 6:266-278.
10. Horie R., Watanabe M., Ishida T., Koiwa T., Aizawa S., Itoh K., Higashihara M., Kadin M.E., Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004, 5:353-364.
11. Iwanaga M., Watanabe T., Utsunomiya A., Okayama A., Uchimaru K., Koh K.R., Ogata M., Kikuchi H., Sagara Y., Uozumi K., et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010, 116:1211-1219. Joint Study on Predisposing Factors of ATL Development investigators.
12. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
13. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J.Biol. Chem. 2004, 279:26243-26250.
14. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
15. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010, 16:286-294.
16. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 2010, 336:25-37.
17. Ramakrishnan P., Wang W., Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004, 21:477-489.
18. Saitoh Y., Yamamoto N., Dewan M.Z., Sugimoto H., Martinez Bruyn V.J., Iwasaki Y., Matsubara K., Qi X., Saitoh T., Imoto I., et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008, 111:5118-5129.
19. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., Möller P., Stilgenbauer S., Pollack J.R., Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008, 112:4202-4212.
20. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
21. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 2009, 10:697-708.
22. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
23. Su I.H., Basavaraj A., Krutchinsky A.N., Hobert O., Ullrich A., Chait B.T., Tarakhovsky A. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 2003, 4:124-131.
24. Su I.H., Dobenecker M.W., Dickinson E., Oser M., Basavaraj A., Marqueron R., Viale A., Reinberg D., Wülfing C., Tarakhovsky A. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005, 121:425-436.
25. Suh J., Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J.Cell. Biochem. 2004, 91:100-117.
26. Thu Y.M., Richmond A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev. 2010, 21:213-226.
27. Trabucchi M., Briata P., Garcia-Mayoral M., Haase A.D., Filipowicz W., Ramos A., Gherzi R., Rosenfeld M.G. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 2009, 459:1010-1014.
28. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szász A.M., Wang Z.C., Brock J.E., Richardson A.L., Weinberg R.A. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
29. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
30. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
31. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
32. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., Utsunomiya A., Koga S., Yamada Y., Kamihira S., et al. Dual targeting of transformed and untransformed HTLV-1-infected Tcells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005, 106:2462-2471.
33. Yamagishi M., Ishida T., Miyake A., Cooper D.A., Kelleher A.D., Suzuki K., Watanabe T. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect. 2009, 11:500-508.
34. Yamaguchi K., Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int. J. Hematol. 2002, 76(Suppl 2):240-245.
35. Yeung M.L., Yasunaga J., Bennasser Y., Dusetti N., Harris D., Ahmad N., Matsuoka M., Jeang K.T. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res. 2008, 68:8976-8985.
36. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., Shiba T., Yang X., Yeh W.C., Mak T.W., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
37. Zarnegar B.J., Yamazaki S., He J.Q., Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. USA 2008, 105:3503-3508.